GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zahravi Pharmacutical Co (XTEH:DZAH1) » Definitions » Debt-to-EBITDA

Zahravi Pharmacutical Co (XTEH:DZAH1) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Zahravi Pharmacutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zahravi Pharmacutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Zahravi Pharmacutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Zahravi Pharmacutical Co's annualized EBITDA for the quarter that ended in . 20 was IRR0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zahravi Pharmacutical Co's Debt-to-EBITDA or its related term are showing as below:

XTEH:DZAH1's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.8
* Ranked among companies with meaningful Debt-to-EBITDA only.

Zahravi Pharmacutical Co Debt-to-EBITDA Historical Data

The historical data trend for Zahravi Pharmacutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zahravi Pharmacutical Co Debt-to-EBITDA Chart

Zahravi Pharmacutical Co Annual Data
Trend
Debt-to-EBITDA

Zahravi Pharmacutical Co Semi-Annual Data
Debt-to-EBITDA

Competitive Comparison of Zahravi Pharmacutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Zahravi Pharmacutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zahravi Pharmacutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zahravi Pharmacutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zahravi Pharmacutical Co's Debt-to-EBITDA falls into.



Zahravi Pharmacutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zahravi Pharmacutical Co's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Zahravi Pharmacutical Co's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.


Zahravi Pharmacutical Co  (XTEH:DZAH1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zahravi Pharmacutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zahravi Pharmacutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zahravi Pharmacutical Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18th km of Karaj Special Road, Darupakhsh Street, Darupakhsh Factories, Entrance No. 2, No. 23, Tehran, IRN
Zahravi Pharmacutical Co is engaged in the pharmaceutical sector. It produces various tablets, capsules, injections, and soft gel capsules. Some of its products are Cograft, Iminoral, Clexaparin, Roaccutane, and others.

Zahravi Pharmacutical Co Headlines

No Headlines